A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer

Abstract

BackgroundBladder cancer is an aggressive and heterogeneous disease associated with high morbidity and mortality. And poliovirus receptor (PVR or CD155) played crucial roles in tumor immune microenvironment and cancer development. However, their association remains obscure.MethodsA total of 797 patients from TCGA and GEO databases were employed in our study, in which 285 cases were set as the training cohort and 512 were defined as the validation cohort. Our own Xiangya cohort with 57 samples was also used for the validation. Survival differences were evaluated by Kaplan-Meier analysis between groups. The immune infiltration was evaluated by ESTIMATE, TIMER, and CIBERSORT algorithms. The risk signature was constructed by LASSO Cox regression analysis. And a nomogram model was generated subsequent to the multivariate Cox proportional hazards analysis to predict 3- and 5-year survival of patients with bladder cancer.ResultsPVR was overexpressed across various cancers including bladder cancer and related to poorer overall survival in bladder urothelial carcinoma (BLCA). Samples with higher World Health Organization (WHO) grade or higher tumor stage tended to express higher level of PVR. And PVR-related genes were involved in several immune processes and oncological pathways. When the patients were divided into low- and high-risk groups based on their risk scores, we found that patients in the high-risk group had shorter overall survival time. Besides, samples with high risk were consistently correlated with tumor hallmarks and higher abundance of immune infiltration. Additionally, chemotherapy showed potent efficacy in high-risk group. Moreover, a nomogram including clinicopathologic features and the established risk signature could predict 3- and 5-year survival in patients with bladder cancer.ConclusionOur study revealed that PVR was overexpressed and related to poor prognosis in bladder cancer. A risk signature and nomogram model based on PVR-related genes could predict the prognosis and therapeutic efficacy and were also associated with the immune infiltration in bladder cancer.

G-Protein Subunit Gamma 4 as a Potential Biomarker for Predicting the Response of Chemotherapy and Immunotherapy in Bladder Cancer

“…An effective biomarker to predict ICB immunotherapy response is important for precise treatment. However, although CD8 + T effector signatures, hypoxia-related genes, and PVR-related genes have been shown to predict BLCA immunotherapy [40][41][42], these indicators often involve more genes and are difficult to measure. GNG4 as a single gene may have the advantage compared with these biomarkers.…”

Expression of Membranous CD155 Is Associated with Aggressive Phenotypes and a Poor Prognosis in Patients with Bladder Cancer

“…CD155 is rarely expressed in most normal tissues, but is overexpressed in various carcinomas [7][8][9][10][11][12]. In terms of BC, Cong et al [18] analyzed 797 patients from The Cancer Genome Atlas and Genome Expression Omnibus to establish a relationship between the mRNA expression of CD155 and the prognosis of several cancer types including BC. Zhang et al [19] investigated 228 BC patients who underwent RC and reported that CD155 protein was significantly overexpressed on the membrane of tumor cells compared to matched normal urothelial cells.…”

DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy

“…Indeed, in addition to being expressed in virusinfected cells (43), these ligands are overexpressed in several hematological and solid tumors (5, 50-52). Noticeably, these ligands, in particular PVR, are potential prognostic markers in AML (53,54), MM (55), hepatocellular carcinoma (56), and bladder urothelial carcinoma (BLCA) (57). As we have previously reported, PVR expression is directly under the control of p53 at promoter level (47), whilst the transcriptional regulation of Nectin-2 remains more widely to be explored (58).…”